DE07108593T1 - Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten - Google Patents
Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten Download PDFInfo
- Publication number
- DE07108593T1 DE07108593T1 DE07108593T DE07108593T DE07108593T1 DE 07108593 T1 DE07108593 T1 DE 07108593T1 DE 07108593 T DE07108593 T DE 07108593T DE 07108593 T DE07108593 T DE 07108593T DE 07108593 T1 DE07108593 T1 DE 07108593T1
- Authority
- DE
- Germany
- Prior art keywords
- xanthan gum
- ophthalmic composition
- buffer
- active ingredient
- sodium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000230 xanthan gum Substances 0.000 title claims abstract 19
- 229920001285 xanthan gum Polymers 0.000 title claims abstract 19
- 229940082509 xanthan gum Drugs 0.000 title claims abstract 19
- 235000010493 xanthan gum Nutrition 0.000 title claims abstract 19
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract 3
- 210000000981 epithelium Anatomy 0.000 claims abstract 2
- 239000000872 buffer Substances 0.000 claims 11
- 239000007951 isotonicity adjuster Substances 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 239000003963 antioxidant agent Substances 0.000 claims 5
- 235000006708 antioxidants Nutrition 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 4
- 235000019800 disodium phosphate Nutrition 0.000 claims 4
- 239000008213 purified water Substances 0.000 claims 4
- 239000001509 sodium citrate Substances 0.000 claims 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 4
- 238000007792 addition Methods 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 239000002831 pharmacologic agent Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000003560 epithelium corneal Anatomy 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 239000002637 mydriatic agent Substances 0.000 claims 1
- 230000002911 mydriatic effect Effects 0.000 claims 1
- 229960000808 netilmicin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000009993 protective function Effects 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Xanthangummi
für ophthalmische
Anwendungen als aktiver Bestandteil in einem Medikament.
Claims (18)
- Xanthangummi für ophthalmische Anwendungen als aktiver Bestandteil in einem Medikament.
- Die Anwendung von Xanthangummi als aktiver Bestandteil eines Medikaments für die Herstellung eines Mittels zur Behandlung ophthalmischer Epithelwunden.
- Die Anwendung von Xanthangummi nach Anspruch 2 gemeinsam mit einem unter den Infektions- und Entzündungshemmern, Anesthetika oder Mydriatika ausgewählten Medikament.
- Die Anwendung von Xanthangummi nach einem der Ansprüche 2 oder 3, bei der das Epithel das Hornhautepithel ist.
- Anwendung von Xanthangummi nach einem der Ansprüche 2 bis 4 zum Fördern der Ausbreitung von Epithelzellen.
- Ophthalmisches Reepithelisierungsmittel im Wesentlichen in Form eines vorgeformten Gels aus Xanthangummi als aktiver Bestandteil sowie pharmakologisch akzeptablen Zusätzen.
- Ophthalmische Zusammensetzung nach Anspruch 6, bei der der aktive Bestandteil Xanthangummi in Mengen von 0,7% bis 5% des Gesamtvolumens des vorgeformten Gels aufweist.
- Ophthalmische Zusammensetzung nach Anspruch 6, in der der Xanthangummi in Mengen von 0,8% bis 3% des Gesamtvolumens des vorgeformten Gels vorliegt.
- Ophthalmische Zusammensetzung nach Anspruch 6, in der der Xanthangummi in Mengen von 0,9% bis 1,5% des Gesamtvolumens des vorgeformten Gels vorliegt.
- Ophthalmische Zusammensetzung nach einem der Ansprüche 6 bis 9, in der die Zusätze u. a. isotonische Wirkstoffe, Puffer, Lösungsmittel, Antioxidantien, pH-Einsteller u. dergl. sein können.
- Ophthalmische Zusammensetzung nach Anspruch 10, bei der die Zusätze ionisch oder nichtionisch sowie deren Gemische, die Puffer Phosphat oder Borat, Acetat, Citrat/Acetat, TrisHCl oder auf Histidin- oder Argininbasis, die Antioxidantien Natriumcitrat, -ascorbat oder -sulfat, die pH-Einsteller organische oder anorganische Säuren oder Basen ggf. gemeinsam mit ihren Salzformen, und die Lösungsmittel bzw. Träger Wasser oder ein Öl/Wasser-Gemisch sein können.
- Ophthalmische Zusammensetzung bestehend aus:
Xanthangummi 1,0000 g akt. Bestandteil, reepithelisierend Natriumchlorid 0,3500 g Isotonikum Natriumphosphat dibasisch.12H2O 0,3638 g Puffer Natriumphosphat monobasisch.H2O 0,0354 g Puffer Glycerol 1,0000 g Isotonikum gereinigtes Wasser q. s. auf 100,0 ml Lösungsmittel - Ophthalmische Zusammensetzung bestehend aus:
Xanthangummi 1,0000 g akt. Bestandteil, reepithelisierend Natriumchlorid 0,3500 g Isotonikum Kaliumchlorid 0,1500 g Isotonikum Magnesiumchlorid.6H2O 0,0120 g Isotonikum Calciumchlorid 0,0084 g Isotonikum Natriumphosphat dibasisch.12H2O 0,0890 g Puffer Natriumphosphat monobasisch.H2O 0,0069 g Puffer Natriumcitrat.2H2O 0,0590 g Puffer/Antioxidans Glycerol 1,0000 g Isotonikum gereinigtes Wasser q. s. auf 100,0 ml Lösungsmittel - Ophthalmische Zusammensetzung bestehend aus:
Dexamethasondinatrium 0,1500 g aktiver Bestandteil Xanthangummi 1,0000 g akt. Bestandteil, reepithelisierend Natriumphosphat dibasisch.12H2O 0,5000 g Puffer Natriumphosphat monobasisch.H2O 0,1465 g Puffer Natriumcitrat.2H2O 2,1000 g Antioxidans gereinigtes Wasser q. s. auf 100,0 ml Lösungsmittel - Ophthalmische Zusammensetzung bestehend aus:
Dexamethasondinatrium 0,1500 g aktiver Bestandteil Netilmicinsulfat-Äquival. auf 0,4550 g aktiver Bestandteil Xanthangummi 1,0000 g akt. Bestandteil, reepithelisierend Natriumphosphat dibasisch.12H2O 0,5000 g Puffer Natriumphosphat monobasisch.H2O 0,1465 g Puffer Natriumcitrat.2H2O 2,1000 g Antioxidans gereinigtes Wasser q. s. auf 100,0 ml Lösungsmittel - Verfahren zur Herstellung einer reepithelisierenden ophthalmischen Zusammensetzung nach einem der Ansprüche 6 bis 15 mit folgenden Phasen: – Lösen der adäquaten Menge von Zusätzen in einem adäquaten Volumen Wasser; – Zugabe anderer pharmakologischer Wirkstoffe nach Bedarf; – Sterilisieren der Lösung; – Dispergieren einer vorbestimmten Menge Xanthangummi in Wasser ohne Rühren, um eine Klumpenbildung zu vermeiden; – Sterilisieren der Dispersion; – Zugabe der Zusätzelösung zur Xanthangummidispersion sowie ggf. weiterer pharmakologischer Wirkstoffe unter Rühren bei Vermeidung von Turbulenzen; – aseptisches Verteilen des in den vorgehenden Phasen erhaltenen Gels auf geeignete Behälter.
- Verfahren nach Anspruch 16, bei dem die Dispersionsphase des Xanthangummis durch Homogenisieren erfolgt.
- Ophthalmische Zusammensetzung nach einem der Ansprüche 5–15, die eine mechanisch schützende Funktion aufweist.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02425274A EP1358883B8 (de) | 2002-04-30 | 2002-04-30 | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen |
| EP07108593A EP1913948B1 (de) | 2002-04-30 | 2002-04-30 | Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE07108593T1 true DE07108593T1 (de) | 2008-12-04 |
Family
ID=28799773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60221227T Expired - Lifetime DE60221227T2 (de) | 2002-04-30 | 2002-04-30 | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen |
| DE07108593T Pending DE07108593T1 (de) | 2002-04-30 | 2002-04-30 | Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60221227T Expired - Lifetime DE60221227T2 (de) | 2002-04-30 | 2002-04-30 | Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US8912164B2 (de) |
| EP (2) | EP1358883B8 (de) |
| JP (2) | JP4837912B2 (de) |
| CN (1) | CN100502884C (de) |
| AT (2) | ATE367165T1 (de) |
| AU (1) | AU2003230224B2 (de) |
| BR (1) | BR0304655A (de) |
| CA (2) | CA2484020C (de) |
| DE (2) | DE60221227T2 (de) |
| DK (1) | DK1358883T3 (de) |
| ES (2) | ES2304913T3 (de) |
| MX (1) | MXPA04010668A (de) |
| PT (1) | PT1358883E (de) |
| RU (1) | RU2297230C2 (de) |
| WO (1) | WO2003092706A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2304913T3 (es) * | 2002-04-30 | 2012-03-01 | Sifi S.P.A. | Composiciones farmacéuticas reepitelializantes que contienen goma de xantano. |
| JP2005530768A (ja) | 2002-05-09 | 2005-10-13 | メディジーンズ | 血漿または血清を含有した創傷治療用医薬組成物 |
| JP4948176B2 (ja) * | 2004-09-28 | 2012-06-06 | 千寿製薬株式会社 | キサンタンガムおよびアミノ酸を含有する眼科用組成物 |
| ITRM20050443A1 (it) * | 2005-08-12 | 2007-02-13 | Opocrin Spa | Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea. |
| JP5244584B2 (ja) * | 2006-03-23 | 2013-07-24 | 千寿製薬株式会社 | キサンタンガムおよびブドウ糖を含有する眼科用組成物 |
| US20110117189A1 (en) * | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| JP5620168B2 (ja) * | 2010-06-30 | 2014-11-05 | Ｄｓｐ五協フード＆ケミカル株式会社 | キシログルカン−カチオン複合体及びそれを含有する安定化組成物 |
| IT1404145B1 (it) * | 2010-12-27 | 2013-11-15 | Altergon Sa | Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi |
| CN104144690B (zh) * | 2011-11-24 | 2017-12-29 | 东洋精糖株式会社 | 角结膜保护剂或角结膜障碍抑制剂 |
| WO2016185935A1 (ja) * | 2015-05-18 | 2016-11-24 | 柿原秀己 | 抗菌物質及び液状抗菌剤並びに液状抗菌剤の製造方法 |
| JP6955497B2 (ja) * | 2015-12-29 | 2021-10-27 | インターベット インターナショナル ベー． フェー． | コクシジウム症ワクチン |
| CN106236704A (zh) * | 2016-08-30 | 2016-12-21 | 上海昊海生物科技股份有限公司 | 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法 |
| CN114245737A (zh) | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
| IT202000002296A1 (it) * | 2020-02-06 | 2021-08-06 | Sifi Spa | Formulazioni topiche oftalmiche a base di xantano con ridotta posologia |
| MX2021003369A (es) * | 2021-03-22 | 2022-09-23 | Laboratorios Grin S A De C V | Lágrima ocular triple. |
| IT202200000821A1 (it) * | 2022-01-19 | 2023-07-19 | Sifi Spa | Formulazioni topiche oftalmiche a base di xantano con ridotta posologia |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| US4370324A (en) | 1980-09-17 | 1983-01-25 | Bernstein Joel E | Method and composition for treating and preventing irritation of the eyes |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
| US4826872A (en) | 1986-12-03 | 1989-05-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for treatment of cataract |
| JPH0723317B2 (ja) * | 1988-03-17 | 1995-03-15 | 生化学工業株式会社 | 角膜上皮層障害症治療剤 |
| JPH0651638B2 (ja) * | 1989-02-13 | 1994-07-06 | 新技術事業団 | 角膜上皮創傷治療用点眼剤 |
| US5271943A (en) * | 1989-10-27 | 1993-12-21 | Scott Health Care | Wound gel compositions containing sodium chloride and method of using them |
| IT1243435B (it) * | 1990-10-05 | 1994-06-10 | Altergon Sa | Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti |
| US5804213A (en) * | 1991-10-09 | 1998-09-08 | Lectec Corporation | Biologically active aqueous gel wound dressing |
| US6277365B1 (en) * | 1997-09-18 | 2001-08-21 | Bausch & Lomb Incorporated | Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| WO2000042986A2 (de) * | 1999-01-19 | 2000-07-27 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Künstliche tränenflüssigkeit in gelform |
| AU2000269264A1 (en) * | 2000-08-23 | 2002-03-04 | Eidgenossische Technische Hochschule Zurich (Eth) | Treatment of trauma, and other indications |
| AU2002232437A1 (en) * | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic lubricating solution adapted for use in lasik surgery |
| ES2304913T3 (es) * | 2002-04-30 | 2012-03-01 | Sifi S.P.A. | Composiciones farmacéuticas reepitelializantes que contienen goma de xantano. |
-
2002
- 2002-04-30 ES ES07108593T patent/ES2304913T3/es not_active Expired - Lifetime
- 2002-04-30 AT AT02425274T patent/ATE367165T1/de active
- 2002-04-30 AT AT07108593T patent/ATE528009T1/de not_active IP Right Cessation
- 2002-04-30 DE DE60221227T patent/DE60221227T2/de not_active Expired - Lifetime
- 2002-04-30 DK DK02425274T patent/DK1358883T3/da active
- 2002-04-30 DE DE07108593T patent/DE07108593T1/de active Pending
- 2002-04-30 EP EP02425274A patent/EP1358883B8/de not_active Expired - Lifetime
- 2002-04-30 EP EP07108593A patent/EP1913948B1/de not_active Expired - Lifetime
- 2002-04-30 ES ES02425274T patent/ES2290264T3/es not_active Expired - Lifetime
- 2002-04-30 PT PT02425274T patent/PT1358883E/pt unknown
-
2003
- 2003-04-24 CA CA2484020A patent/CA2484020C/en not_active Expired - Lifetime
- 2003-04-24 BR BR0304655-9A patent/BR0304655A/pt not_active Application Discontinuation
- 2003-04-24 AU AU2003230224A patent/AU2003230224B2/en not_active Expired
- 2003-04-24 WO PCT/IT2003/000257 patent/WO2003092706A1/en active Application Filing
- 2003-04-24 CN CNB038095068A patent/CN100502884C/zh not_active Expired - Lifetime
- 2003-04-24 RU RU2004131550/15A patent/RU2297230C2/ru active
- 2003-04-24 CA CA2749172A patent/CA2749172C/en not_active Expired - Lifetime
- 2003-04-24 MX MXPA04010668A patent/MXPA04010668A/es active IP Right Grant
- 2003-04-24 US US10/512,521 patent/US8912164B2/en active Active
- 2003-04-24 JP JP2004500890A patent/JP4837912B2/ja not_active Expired - Lifetime
-
2008
- 2008-02-14 US US12/031,495 patent/US20080139522A1/en not_active Abandoned
- 2008-02-14 US US12/031,518 patent/US20080146530A1/en not_active Abandoned
- 2008-02-14 US US12/031,483 patent/US20080139502A1/en not_active Abandoned
-
2011
- 2011-01-14 JP JP2011005761A patent/JP5203472B2/ja not_active Expired - Lifetime
-
2016
- 2016-02-25 US US15/054,090 patent/US20160166601A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE07108593T1 (de) | Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten | |
| DE2827018C2 (de) | ||
| DE69535570T2 (de) | Antimykotische Zusammensetzung zur äusserlichen Anwendung, die im Stratum Corneum retentiv ist | |
| DE69328192T4 (de) | Injizierbare Arzneizubereitungen enthaltend Taxanderivate | |
| DE69927963T2 (de) | Gelierbare pharmazeutische zusammensetzungen | |
| DE69116135T2 (de) | Verwendung von alpha-tocopherolphosphat oder eines derivates davon zur herstellung kosmetischer dermatologischer oder pharmazeutischer präparate | |
| DE60001223T2 (de) | Tris enthaltende propofol-formulierung | |
| KR870009720A (ko) | 서방형 신규 제약 제제물 | |
| DE652754T1 (de) | Medikamente zur topischen anwendung von sexualhormonen zur behandlung des trockenen auges, und verfahren zu ihrer herstellung und anwendung. | |
| DE2817335A1 (de) | Antibiotische tetracyclinhaltige mittel | |
| DE4215450A1 (de) | Pharmazeutisches mittel | |
| CH696260A5 (de) | Fulvestrant Formulierung. | |
| DE60109530T2 (de) | Amorphe Mupirocin enthaltende Arzneimittel | |
| DE3879811T2 (de) | Pharmazeutische Zusammensetzung und ihre Verwendung. | |
| CH643456A5 (de) | Pharmazeutische zubereitung. | |
| DE69011399T2 (de) | Stabile flüssige Formulierung von 5-Aminosalizylsäure. | |
| EP1032379A1 (de) | Zusammensetzung mit azelainsäure | |
| DE60117248T2 (de) | Parenterale lösung, welche amiodaron enthält | |
| DE69000640T2 (de) | Stabilisierte kalcitoninzubereitung. | |
| DE60316574T2 (de) | Stabile augentropfen enthaltend latanoprost als wirkstoff | |
| DE559502T1 (de) | Topisches Behandlungsmittel enthaltend Lipidvesikeln die mindestens ein Mineralwasser einkapseln. | |
| CH676549A5 (de) | ||
| DE68906513T2 (de) | Topisch anzuwendende diclofenac enthaltende arzneizubereitungen. | |
| DE69122229T2 (de) | Penciclovir enthaltende pharmazeutische formulierung | |
| JPS63305930A (ja) | 乳化組成物 |